Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent vs Continuous Erlotinib with XELOX in mCRC
NCT01243047Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2007
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in metastatic colorectal cancer (mCRC), sponsored by The Chinese University of Hong Kong. Started Sep 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01243047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01243047.